Melinta Therapeutics, Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes various anti-infectives for the treatment of bacterial infectious diseases in North America. It offers Baxdela, a monotherapy treatment of adult patients with acute bacterial skin or skin structure infections (ABSSSIs); Vabomere, an IV antibiotic used in treatment of gram-negative infections; Orbactiv, an IV antibiotic of the lipoglycopeptide class for the treatment of adult patients with ABSSSIs; and Minocin, a IV antibiotic of the tetracycline class with activity against gram-positive and gram-negative pathogens.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone908-617-1309
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$96.43 million
Profitability
Miscellaneous
Employees290
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Melinta Therapeutics (NASDAQ:MLNT) Frequently Asked Questions
What is Melinta Therapeutics' stock symbol?
Melinta Therapeutics trades on the NASDAQ under the ticker symbol "MLNT."
When did Melinta Therapeutics' stock split? How did Melinta Therapeutics' stock split work?
Melinta Therapeutics shares reverse split on the morning of Friday, February 22nd 2019. The 1-5 reverse split was announced on Thursday, February 21st 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 21st 2019. An investor that had 100 shares of Melinta Therapeutics stock prior to the reverse split would have 20 shares after the split.
How were Melinta Therapeutics' earnings last quarter?
Melinta Therapeutics Inc (NASDAQ:MLNT) posted its earnings results on Friday, August, 9th. The biotechnology company reported ($3.07) earnings per share for the quarter, missing the Zacks' consensus estimate of ($2.57) by $0.50. The biotechnology company earned $15.96 million during the quarter, compared to the consensus estimate of $14 million. Melinta Therapeutics had a negative return on equity of 60.39% and a negative net margin of 135.23%. View Melinta Therapeutics' Earnings History.
When is Melinta Therapeutics' next earnings date?
What guidance has Melinta Therapeutics issued on next quarter's earnings?
Melinta Therapeutics issued an update on its second quarter 2019 earnings guidance on Tuesday, July, 16th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $13.8 million.
What price target have analysts set for MLNT?
7 brokers have issued 1 year price objectives for Melinta Therapeutics' stock. Their forecasts range from $5.00 to $70.00. On average, they expect Melinta Therapeutics' stock price to reach $32.10 in the next twelve months. This suggests a possible upside of 858.2% from the stock's current price. View Analyst Price Targets for Melinta Therapeutics.
What is the consensus analysts' recommendation for Melinta Therapeutics?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Melinta Therapeutics in the last year. There are currently 2 sell ratings, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Melinta Therapeutics.
What are Wall Street analysts saying about Melinta Therapeutics stock?
Here are some recent quotes from research analysts about Melinta Therapeutics stock:
- 1. According to Zacks Investment Research, "Melinta Therapeutics, Inc. develops and commercializes novel antibiotics designed to provide new and better therapeutic solutions. Melinta's lead product is Baxdela, an antibiotic approved by the US FDA for use in the treatment of acute bacterial skin and skin structure infections (ABSSSI). Melinta also has an extensive pipeline of preclinical and clinical stage products that were developed internally or assumed under the 2017 acquisition of Cempra, Inc. This pipeline includes many important classes of antibiotics, each targeted at a different segment of the anti-infective market. Melinta is headquartered in New Haven, CT. " (8/17/2019)
- 2. HC Wainwright analysts commented, "We note that after a brief spike to $4.98 late Tuesday morning, MLNT shares closed last night at $3.75 per share, down $0.43 (-10.3%) since the release, versus NBI essentially flat (-0.4%) over the same period. First, the expected net product sales figure of $13.8M in the quarter is a slight 3% increase from our recently-lowered prior estimate of $13.4M. for CABP by Adjust PT to $13. We have now adjusted our estimate to match guidance. However, with 1H19 net product sales at about $25.6M, net sales growth in 2H19 would need to be at least 49% over 1H19 to meet the full-year 2019 minimum product sales of $63.75M as required by the Deerfield debt facility. This degree of growth acceleration seems unlikely to us the sequential growth in 2Q19 was 17%." (7/18/2019)
- 3. Cantor Fitzgerald analysts commented, ". Post a solid quarter of execution in 1Q19, we reiterate our OW rating and 12-month price target of $15 for MLNT shares. We continue to believe that upward earnings revisions and multiple expansion, from the uptake of its drugs, will drive the stock higher." (5/9/2019)
Has Melinta Therapeutics been receiving favorable news coverage?
News headlines about MLNT stock have been trending negative recently, according to InfoTrie. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Melinta Therapeutics earned a news sentiment score of -2.9 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for Melinta Therapeutics.
Are investors shorting Melinta Therapeutics?
Melinta Therapeutics saw a decline in short interest during the month of August. As of August 31st, there was short interest totalling 894,400 shares, a decline of 11.5% from the July 31st total of 1,011,100 shares. Based on an average daily volume of 2,600,000 shares, the short-interest ratio is currently 0.3 days. Approximately 9.1% of the shares of the stock are sold short. View Melinta Therapeutics' Current Options Chain.
Who are some of Melinta Therapeutics' key competitors?
Some companies that are related to Melinta Therapeutics include American Brivision (Holding) (ABVC), REDHILL BIOPHAR/S (RDHL), BioXcel Therapeutics (BTAI), AVEO Pharmaceuticals (AVEO), XOMA (XOMA), Paratek Pharmaceuticals (PRTK), Applied Therapeutics (APLT), Newron Pharmaceuticals (NWPHF), Hookipa Pharma (HOOK), TAIWAN LIPOSOME/S (TLC), Aldeyra Therapeutics (ALDX), Sol Gel Technologies (SLGL), Strongbridge Biopharma (SBBP), Arcturus Therapeutics (ARCT) and Cerecor (CERC).
What other stocks do shareholders of Melinta Therapeutics own?
Who are Melinta Therapeutics' key executives?
Melinta Therapeutics' management team includes the folowing people:
- Dr. Erin M. Duffy, Chief Scientific Officer & Exec. VP (Age 51)
- Mr. John H. Johnson, CEO & Director (Age 61)
- Dr. Thomas A. Steitz, Co-Founder
- Dr. Peter B. Moore Ph.D., Co-Founder
- Dr. William L. Jorgensen, Co-Founder
Who are Melinta Therapeutics' major shareholders?
Melinta Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.76%), Renaissance Technologies LLC (2.07%), BlackRock Inc. (1.42%), Northern Trust Corp (0.62%), D. E. Shaw & Co. Inc. (0.39%) and Bank of New York Mellon Corp (0.42%). Company insiders that own Melinta Therapeutics stock include David N Gill, Paul Estrem, Sue Cammarata and Vatera Healthcare Partners Llc. View Institutional Ownership Trends for Melinta Therapeutics.
Which major investors are selling Melinta Therapeutics stock?
Which major investors are buying Melinta Therapeutics stock?
MLNT stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Renaissance Technologies LLC, D. E. Shaw & Co. Inc., Jane Street Group LLC, Royal Bank of Canada, Paloma Partners Management Co, Bank of New York Mellon Corp and Parametric Portfolio Associates LLC. Company insiders that have bought Melinta Therapeutics stock in the last two years include David N Gill, Paul Estrem, Sue Cammarata and Vatera Healthcare Partners Llc. View Insider Buying and Selling for Melinta Therapeutics.
How do I buy shares of Melinta Therapeutics?
Shares of MLNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Melinta Therapeutics' stock price today?
One share of MLNT stock can currently be purchased for approximately $3.35.
How big of a company is Melinta Therapeutics?
Melinta Therapeutics has a market capitalization of $46.07 million and generates $96.43 million in revenue each year. The biotechnology company earns $-157,190,000.00 in net income (profit) each year or ($17.72) on an earnings per share basis. Melinta Therapeutics employs 290 workers across the globe.View Additional Information About Melinta Therapeutics.
What is Melinta Therapeutics' official website?
How can I contact Melinta Therapeutics?
Melinta Therapeutics' mailing address is 44 WHIPPANY ROAD, MORRISTOWN NJ, 07960. The biotechnology company can be reached via phone at 908-617-1309 or via email at [email protected]
MarketBeat Community Rating for Melinta Therapeutics (NASDAQ MLNT)
MarketBeat's community ratings are surveys of what our community members think about Melinta Therapeutics and other stocks. Vote "Outperform" if you believe MLNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MLNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
